Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, September 24, 2009
Wed, September 23, 2009 Osiris Therapeutics (OSIR) Has Been On BUYINS.NET Naked Short List For 13 Consecutive Trading Days
September 23, 2009 /M2 PRESSWIRE/ BUYINS.NET, www.buyins.net, announced today that these select companies have been on the NASDAQ, AMEX and NYSE naked short threshold lists for 13 consecutive trading days: Osiris Therapeutics (NASDAQ: OSIR). For a complete list of companies on the naked short lists please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to http://www.buyins.net .
Regulation SHO took effect January 3, 2005, and provides a new regulatory framework governing short selling of securities. It was designed with the objective of simplifying and modernizing short sale regulation and providing controls where they are most needed. At the conclusion of each settlement day, data is provided on securities in which: 1) there are at least 10,000 shares in aggregate failed deliveries for the security for five consecutive settlement days, and 2) these failures constitute at least 0.5% of the issuer's total shares outstanding. Regulation SHO mandates that, if a clearing agent has had a fail-to-deliver position for 13 consecutive settlement days, that clearing agent, and the broker/dealer it clears for, must purchase securities to close out its fail to deliver position.
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a biotechnology company, commercializes stem cell products from adult bone marrow in the United States. The company focuses on developing and marketing products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The companya�s biologic drug candidate, Prochymal, is being evaluated in Phase III clinical trials for four indications, including acute and steroid refractory graft versus host disease (GvHD), Crohn's disease and for the repair of gastrointestinal injury resulting from radiation exposure, and is the stem cell therapeutic granted both Orphan Drug and Fast Track status by the United States Food and Drug Administration (FDA). Prochymal is also being developed for the repair of heart tissue following a heart attack, for protection of pancreatic islet cells in patients with type 1 diabetes, and for the treatment of Chronic Obstructive Pulmonary Disease (COPD). The companya�s pipeline of internally developed biologic drug candidates under evaluation also includes Chondrogen for osteoarthritis in the knee. In 2008, the company entered into a collaboration agreement with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, the company retained the rights to commercialize Prochymal and Chondrogen in the United States and Canada and Genzyme has been granted rights to commercialize Prochymal and Chondrogen in all other countries, except with respect to GvHD in Japan, where Prochymal has previously been licensed to another. The company also has partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In 2008, the company was granted a contract from the U.S. Department of Defense, pursuant to which the company, in partnership with Genzyme, intends to develop and stockpile Prochymal for the repair of gastrointestinal injury resulting from acute radiation exposure. Additionally, the company has partnered with the Juvenile Diabetes Research Foundation (JDRF) for the development of Prochymal as a treatment for the preservation of insulin production in patients with newly diagnosed type 1 diabetes mellitus. Prochymal is the company's biologic drug candidate and is being evaluated in Phase III clinical trials for three indications, including the first line treatment of acute GvHD, steroid refractory acute GvHD and biologics refractory Crohn's disease and is a stem cell therapeutic. Phase III Clinical Triala"Steroid Refractory Acute GvHD: The companya�s Phase III trial to evaluate Prochymal as a treatment for steroid refractory GvHD is a randomized, double blind, placebo controlled study. The trial is investigating patient response to eight infusions of Prochymal administered twice per week for four consecutive weeks. Phase III Clinical Triala"First Line Treatment of Acute GvHD: The companya�s Phase III trial to evaluate Prochymal as a first line treatment for acute GvHD is a randomized, double blind, placebo controlled study designed to enroll up to 184 patients. Phase III Clinical Triala"Biologics Refractory Crohn's Disease: Based on its clinical observations of the effects of Prochymal on the gastrointestinal symptoms of patients with GvHD, the company is developing Prochymal for the treatment of Crohn's disease. The company completed patient enrollment in a Phase II trial for Crohn's disease under a separate Investigational New Drug application (IND). Phase II Clinical Triala"Acute Myocardial Infarction: The company initiated a Phase II clinical trial for Acute Myocardial Infarction in the United States and Canada. Phase II Clinical Triala"Early Onset Type 1 Diabetes: The company initiated a Phase II, 60 patient, placebo controlled study in the United States for the treatment of early onset type 1 diabetes in individuals 18 to 30 years old. The company has entered into a collaborative agreement with the Juvenile Diabetes Research Foundation (JDRF) for this study. Phase II Clinical Triala"Chronic Obstructive Pulmonary Disease: The company completed the enrollment of 62 patients in the Phase II clinical trial evaluating the safety and efficacy of Prochymal in conjunction with standard of care for improving pulmonary function in patients with moderate to severe COPD. The clinical trial is a double-blind, placebo-controlled study. Phase III Clinical Triala"Animal Rulea"Acute Radiation Syndrome: In 2007, the company partnered with Genzyme Corporation to develop Prochymal as a medical countermeasure to nuclear terrorism and other radiological emergencies. In January 2008, the company was granted a contract from the United States Department of Defense (DoD) for the development and stockpiling of Prochymal for the treatment of acute radiation syndrome (ARS). Chondrogen is its biologic drug candidate for the treatment of osteoarthritis and the reduction of pain in the knee. The company completed enrollment of a randomized double-blind, placebo controlled Phase I/II clinical trial evaluating Chondrogen for safety and preliminary efficacy based upon regeneration of meniscus. Prochymal and Chondrogen Development and Commercialization In October 2008, the company entered into a collaboration agreement with Genzyme Corporation for the development and commercialization of Prochymal and Chondrogen. Under the terms of the agreement, the company retains the right to commercialize Prochymal and Chondrogen in the United States and Canada and Genzyme is provided the right to commercialize the treatments in all other countries, except with respect to GvHD in Japan where JCR Pharmaceuticals Co., Ltd. has these rights. Competition Prochymal would compete with Johnson & Johnson, Abbott, Biogen, and UCB. The companya�s other competitoers include Aastrom Biosciences, Advanced Cell Technology, Athersys, Cellerant Therapeutics, Cognate Therapeutics, Cytori Therapeutics, Gamida Cell, Geron, Mesoblast, MultiCell Technologies, Neuronyx, Theradigm, ViaCell and StemCells. History Osiris Therapeutics, Inc. was founded in 1992. The failure to deliver in shares of OSIR has not been resolved and a buy-in is expected.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf . The SqueezeTrigger database of nearly 2.650,000,000 short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each montha�s short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
Contact: Thomas Ronk / CEO / www.BUYINS.net / (800) 715-9999 / tom@buyins.net
